A carregar...
FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
Although regorafenib has demonstrated survival benefits in patients with metastatic colorectal and gastrointestinal stromal tumors, no proven biomarker has been identified for predicting sensitivity to regorafenib. Here, we investigated preclinical activity of regorafenib in gastric and colorectal c...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6026866/ https://ncbi.nlm.nih.gov/pubmed/29573334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12194 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|